timing, page-23

Anything to add on that front?

The Solagran share register consists of many long term holders, both new and old, who believe in the long term objective of the company and many have asked I forward this list of questions for you consideration as many could be answered Pre-AGM and save a lot of time and hassles.

Accordingly on behalf of the many smaller shareholders, I would request that any shareholder announcements are more definitive than subjective in nature to avoid any confusion as to the message which is intended. Adopting this approach would also better support the share price and reduce potential for manipulation, and would be beneficial in restoring management creditability and increasing shareholder awareness as to management’s approach

If you could consider the aforementioned statement in your response to the following, however you wish to reply.

1. What percentage of Ropen will be sold overseas, is it a case of having to supply Russia first and foremost, or the highest price wins?
2. How many courses have been sold to date overseas? And what are current projections, ie supply constrained when, and where?
3. Are overseas sales paid for immediately, by patients, to Solagran, or invoiced to a medical institution. It helps for working out Quarterlies.
4. Could sales numbers and of all SLA products, even if only invoiced, be noted in each quarterly, including which country received what numbers?
5. How are Solagran’s products priced, ie in Roubles, U.S dollars, or Australian dollars? The question, being related to the shift in comparatable value of each currency over time.
6. How far progressed are the BIO-I trials among others?, and will Aids trials be recommenced, as stated, as they were an initial trial ready to continue a few years ago.?.
7. Who, and how many, are the Russian scientists and Administrators of Solalife, what are their roles, and how much of the 28mill shares go to each?
8. Also I believe that SLA directors or Solamind are serving ANZ individually in the Victorian Supreme Court….please fill us in here….is there separate action going on that the casual shareholder is not aware of
9. Is Solalife the new Solamind with all/some of the holders, and is this issue of shares to compensate them for their losses in Opes Prime, or was this planned anyway above what Solamind already owned? If so then will Solamind be returning any monies back to Solagran they could back get from litigation.
10. Is Solamind’s (or any Opes) litigation funded by Solagran in ANY way.
11. If any of the Solalife persons leaves or becomes unable to perform their full duties or becomes deceased, what happens to those shares: can we see the full contract before we vote?
12. Will these shares be issued in accordance with the Remuneration Plan as of the 2007 AGM, E.G. Shares issued under this Plan are to be issued to Participants in July each year at Market Price.
13. The issue of options to Denis and Vagif seem to be double dipping on the agreement from the last AGM, are they being issued above this agreement, or is it to compensate for losses as in Solamind’s case, if so will monies from litigation be returned to SLA? Perhaps the issue of Options, and shares, should be valued in July next year, as SLA’s real value will be clearer then.
14. Will SLA be announcing an independent director in the very near future? Many see this as paramount to a more open and better managed, Solagran.
15. We note liver function tests qualitive/quantative data, ALT AST levels in particular, viral load PCR quantity IU/ml of blood detectable HCV virus in patients’ blood stream have been done for Ropren as per the extract on the Solagran site, but as these results may determine efficacy of treatment, and apparently are recognised worldwide in clinical trials as leading indicators, the actual levels/results are in Question. Can we access these results.
16. When will results be published in Medical Journals and which ones?
17. What is the cost of producing a course of Ropren, i.e. profit margins in this respect?
18. Please explain why Russia receives Ropren at an apparently discounted price, as compared to the rest of the world, and how is this calculated? ; is it because they buy in bulk or Russia, even though they sold all the rights to Bioeffectives ( bar some fairness equation we all feel ), are providing Tomsk as an incentive and SLA have done a ‘LONG TERM DEAL”?, if so….what’s the deal?????......cheap for 10 years then market value?.....Perhaps it’s because of bulk sales?
19. What is the cost of producing a course of Ropren, i.e. profit margins in this respect?
20. What will, in your opinion, liposomal and nano technology do for the amount/percentage of Ropren necessary to achieve the same results as oral treatment?, and regardless of the format of delivery, will it be the same price per treatment? How are the alternative delivery systems progressing? Timelines?
21. Why the need for further contribs to raise money if Ropren demand/sales are imminent? we ask about sales projections over the next quarter, 6 months, 12 months..if they are not met there may be serious problems. If met then the product Ropren has demand and sales and decent income and no need for contribs!
22. If it weren’t for the Solamind Opes and ANZ affair the Sp would be closer to 60c….Why do you all, at the directors table, want to throw shares around now?....is it because you know too much, and pretend you don’t know what you know, and the SP will skyrocket….come clean….
23. What is the real situation on results over the last 6 months?.....Opes didn’t stop trials, did it?